GLP‑1s may lower mortality in patients with diabetes and brain metastases

In a retrospective cohort study of 1,700 propensity‑matched adults with cancer, brain metastases, and type 2 diabetes, GLP‑1 receptor agonist (RA) use was associated with lower all‑cause mortality over 3 years (hazard ratio, 0.63; 95% confidence interval, 0.54–0.72). Associations were generally consistent across cancer types and GLP‑1 agents, except liraglutide. Findings are limited by the observational design and lack of cancer‑specific mortality data.

Clinical takeaway: For patients with type 2 diabetes and brain metastases, GLP‑1 RAs may offer a potential survival advantage, but prospective trials are needed before incorporating this into oncologic decision‑making.

Source:

Chi KY, et al. (2026, March 2). JAMA Netw Open. GLP-1 Receptor Agonist Use and Survival Among Patients With Type 2 Diabetes and Brain Metastases. https://pubmed.ncbi.nlm.nih.gov/41811319/